Overview Dividends

(SIGA) SIGA Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8269171067

Antiviral, Smallpox, TPOXX, Health Security

SIGA EPS (Earnings per Share)

EPS (Earnings per Share) of SIGA over the last years for every Quarter: "2020-09": 0.31, "2020-12": 0.26, "2021-03": -0.02, "2021-06": -0.0034, "2021-09": -0.04, "2021-12": 0.98, "2022-03": -0.01, "2022-06": 0.03, "2022-09": 0.45, "2022-12": -0.01, "2023-03": -0.01, "2023-06": -0.04, "2023-09": -0.01, "2023-12": 1.0164, "2024-03": 0.1436, "2024-06": 0.0255, "2024-09": 0.0187, "2024-12": 0.6409, "2025-03": -0.0057, "2025-06": 0.49, "2025-09": 0,
EPS Growth (3Y CAGR): 10.33%
EPS Trend (3Y Correlation): 20.5%

SIGA Revenue

Revenue of SIGA over the last years for every Quarter: 2020-09: 44.261407, 2020-12: 37.729355, 2021-03: 4.813744, 2021-06: 8.653289, 2021-09: 4.846172, 2021-12: 115.357248, 2022-03: 10.539299, 2022-06: 16.667045, 2022-09: 72.211127, 2022-12: 11.358139, 2023-03: 8.323025, 2023-06: 5.878166, 2023-09: 9.235171, 2023-12: 116.480859, 2024-03: 25.429855, 2024-06: 21.810891, 2024-09: 10.009781, 2024-12: 81.468823, 2025-03: 7.040815, 2025-06: 81.120004, 2025-09: 2.62,
Revenue Growth (3Y CAGR): -41.34%
Revenue Trend (3Y Correlation): 9.5%
Risk via 10d forecast
Volatility 62.6%
Value at Risk 5%th 92.4%
Reward
Sharpe Ratio 0.02
Alpha Jensen -24.72
Character
Hurst Exponent 0.432
Beta 0.972
Drawdowns 3y
Max DD 56.39%
Mean DD 33.87%

Description: SIGA SIGA Technologies October 24, 2025

SIGA Technologies, Inc. (NASDAQ:SIGA) is a commercial-stage biopharma focused on the U.S. health-security market, best known for its FDA-approved antiviral TPOXX, the only licensed treatment for smallpox.

Key metrics as of the latest filing (Q2 2024): cash and short-term investments of roughly $140 million, a net loss of $32 million for the trailing twelve months, and a market-cap near $350 million. The company’s revenue is driven almost entirely by government contracts for TPOXX, which together with the broader biodefense budget (projected to grow at ~4% CAGR) constitute its primary economic driver.

Sector trends that affect SIGA include heightened federal spending on pandemic preparedness and the expanding “health-security” niche, which has attracted increased R&D incentives and potential partnership opportunities with defense contractors.

For a deeper, data-rich analysis of SIGA’s valuation and peer landscape, you may find ValueRay’s research tools helpful.

SIGA Stock Overview

Market Cap in USD 468m
Sub-Industry Pharmaceuticals
IPO / Inception 1997-09-09
Return 12m vs S&P 500 -16.2%
Analyst Rating -

SIGA Dividends

Dividend Yield 9.66%
Yield on Cost 5y 10.62%
Yield CAGR 5y 15.47%
Payout Consistency 98.8%
Payout Ratio 53.3%

SIGA Growth Ratios

CAGR -5.17%
CAGR/Max DD Calmar Ratio -0.09
CAGR/Mean DD Pain Ratio -0.15
Current Volume 453.7k
Average Volume 329.8k

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (74.5m TTM) > 0 and > 6% of Revenue (6% = 10.3m TTM)
FCFTA 0.50 (>2.0%) and ΔFCFTA 13.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 117.8% (prev 91.17%; Δ 26.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.50 (>3.0%) and CFO 116.6m > Net Income 74.5m (YES >=105%, WARN >=100%)
Net Debt (-172.0m) to EBITDA (92.4m) ratio: -1.86 <= 3.0 (WARN <= 3.5)
Current Ratio 9.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (71.6m) change vs 12m ago -0.23% (target <= -2.0% for YES)
Gross Margin 76.29% (prev 78.34%; Δ -2.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 80.69% (prev 88.93%; Δ -8.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -18.20 (EBITDA TTM 92.4m / Interest Expense TTM -5.05m) >= 6 (WARN >= 3)

Altman Z'' 6.70

(A) 0.88 = (Total Current Assets 227.7m - Total Current Liabilities 24.8m) / Total Assets 231.6m
(B) -0.16 = Retained Earnings (Balance) -37.6m / Total Assets 231.6m
(C) 0.43 = EBIT TTM 91.9m / Avg Total Assets 213.5m
(D) -1.34 = Book Value of Equity -37.6m / Total Liabilities 28.1m
Total Rating: 6.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 83.74

1. Piotroski 4.50pt = -0.50
2. FCF Yield 39.17% = 5.0
3. FCF Margin 67.52% = 7.50
4. Debt/Equity 0.00 = 2.50
5. Debt/Ebitda -1.86 = 2.50
6. ROIC - WACC (= 23.16)% = 12.50
7. RoE 35.26% = 2.50
8. Rev. Trend 9.54% = 0.72
9. EPS Trend 20.50% = 1.03

What is the price of SIGA shares?

As of November 13, 2025, the stock is trading at USD 6.21 with a total of 453,671 shares traded.
Over the past week, the price has changed by -26.33%, over one month by -24.82%, over three months by -33.23% and over the past year by -2.86%.

Is SIGA Technologies a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, SIGA Technologies (NASDAQ:SIGA) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 83.74 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SIGA is around 5.48 USD . This means that SIGA is currently overvalued and has a potential downside of -11.76%.

Is SIGA a buy, sell or hold?

SIGA Technologies has no consensus analysts rating.

What are the forecasts/targets for the SIGA price?

Issuer Target Up/Down from current
Wallstreet Target Price 17.5 182.3%
Analysts Target Price 17.5 182.3%
ValueRay Target Price 6.2 -0.6%

SIGA Fundamental Data Overview November 11, 2025

Market Cap USD = 468.3m (468.3m USD * 1.0 USD.USD)
P/E Trailing = 6.3495
P/E Forward = 5.6275
P/S = 2.7189
P/B = 3.0618
Beta = 0.972
Revenue TTM = 172.2m USD
EBIT TTM = 91.9m USD
EBITDA TTM = 92.4m USD
Long Term Debt = 546.8k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 546.8k USD (from shortTermDebt, last fiscal year)
Debt = 546.8k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -172.0m USD (from netDebt column, last quarter)
Enterprise Value = 296.9m USD (468.3m + Debt 546.8k - CCE 172.0m)
Interest Coverage Ratio = -18.20 (Ebit TTM 91.9m / Interest Expense TTM -5.05m)
FCF Yield = 39.17% (FCF TTM 116.3m / Enterprise Value 296.9m)
FCF Margin = 67.52% (FCF TTM 116.3m / Revenue TTM 172.2m)
Net Margin = 43.23% (Net Income TTM 74.5m / Revenue TTM 172.2m)
Gross Margin = 76.29% ((Revenue TTM 172.2m - Cost of Revenue TTM 40.8m) / Revenue TTM)
Gross Margin QoQ = 61.75% (prev 68.50%)
Tobins Q-Ratio = 1.28 (Enterprise Value 296.9m / Total Assets 231.6m)
Interest Expense / Debt = 162.9% (Interest Expense 890.6k / Debt 546.8k)
Taxrate = 23.82% (-1.99m / -8.36m)
NOPAT = 70.0m (EBIT 91.9m * (1 - 23.82%))
Current Ratio = 9.17 (Total Current Assets 227.7m / Total Current Liabilities 24.8m)
Debt / Equity = 0.00 (Debt 546.8k / totalStockholderEquity, last quarter 203.5m)
Debt / EBITDA = -1.86 (Net Debt -172.0m / EBITDA 92.4m)
Debt / FCF = -1.48 (Net Debt -172.0m / FCF TTM 116.3m)
Total Stockholder Equity = 211.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 32.15% (Net Income 74.5m / Total Assets 231.6m)
RoE = 35.26% (Net Income TTM 74.5m / Total Stockholder Equity 211.2m)
RoCE = 43.40% (EBIT 91.9m / Capital Employed (Equity 211.2m + L.T.Debt 546.8k))
RoIC = 32.75% (NOPAT 70.0m / Invested Capital 213.7m)
WACC = 9.59% (E(468.3m)/V(468.9m) * Re(9.60%) + (debt cost/tax rate unavailable))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.36%
[DCF Debug] Terminal Value 76.55% ; FCFE base≈98.4m ; Y1≈121.4m ; Y5≈207.1m
Fair Price DCF = 37.28 (DCF Value 2.67b / Shares Outstanding 71.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 20.50 | EPS CAGR: 10.33% | SUE: 0.0 | # QB: 0
Revenue Correlation: 9.54 | Revenue CAGR: -41.34% | SUE: 0.44 | # QB: 0

Additional Sources for SIGA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle